logo
logo
AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
Flexible Plans • $39/mo or $29/mo annual
AI + real-time funding intelligence
Never see duplicates in your feed
INDUSTRY FIRST

Tricares Successfully Closes Series C Financing, Raising €51M To Fund Further Development And Clinical Trials Of Minimally Invasive Treatment For Tricuspid Regurgitation

Dec 06, 2022over 2 years ago

Amount Raised

€51 Million

Round Type

series c

ParisMedical DeviceMedicalBiotechnologyHealth Care

Description

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Company Information

Company

TRiCares

Location

Paris, Texas, United States

About

TRiCares is developing a transcatheter-based tricuspid valve replacement system aimed at addressing the need for a better treatment for this frequent and severe disease that avoids open heart surgery. Frederik Groenewegen, General Partner at 415 Capital, commented: “TRiCares is developing what we believe has the potential to become a best-in-class therapy option to restore quality of life for millions of patients suffering from tricuspid regurgitation.

FundzWatch™ Score

62
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech